Therefore, we undertook a retrospective study of consecutive patients with HER2-positive breast cancer referred to a dedicated cardio-oncology service in a quaternary care institution managed using a strategy of permissive cardiotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.